Mild To Moderate Plaque Psoriasis Market Summary

Mild To Moderate Plaque Psoriasis Market Insights and Forecast

• The Mild-to-Moderate Plaque Psoriasis Market Size is anticipated to increase with a notable CAGR during the forecast period (2025-2034).
• The leading Mild-to-moderate Plaque Psoriasis Companies such as AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others.
• Most Psoriasis Patients (78%) have mild or moderate illness ( 10% body surface area involved), with mild disease accounting for 50% of cases (3% body surface area involved). Only 2% of individuals have a body surface area involvement greater than 50%. 

Request for Unlocking the Sample Page of the "Mild-to-moderate Plaque Psoriasis Treatment Market"

Factors contributing to the Growth of the "Mild to Moderate Plaque Psoriasis Market

• Rising Prevalence and Diagnosis Rates

Plaque Psoriasis represents the most common form of psoriasis, with mild-to-moderate cases accounting for a significant proportion of the patient population. Increasing global prevalence, coupled with improved diagnostic capabilities and heightened disease awareness, is expanding the treatable patient pool. Earlier diagnosis and proactive disease management strategies are further fueling market demand.

• Advancements in Topical and Systemic Therapies

Innovation in treatment options remains a major growth driver. While topical corticosteroids, vitamin D analogs, and combination therapies continue to be first-line treatments, the development of novel topical formulations with improved efficacy and safety profiles is enhancing patient adherence. Additionally, the growing availability of oral small molecules and targeted systemic therapies suitable for moderate cases is broadening treatment possibilities beyond traditional approaches.

• Increasing Focus on Quality of Life

Mild-to-moderate plaque psoriasis significantly impacts patients’ physical comfort, psychological well-being, and social interactions. Growing recognition of the disease’s burden on quality of life has encouraged both patients and healthcare providers to seek more effective and long-term management strategies. This shift from symptom control to comprehensive disease management is contributing to increased treatment uptake.

• Expanding Healthcare Access and Reimbursement Support

Improved healthcare infrastructure in emerging markets and favorable reimbursement policies in developed regions are facilitating access to advanced therapies. As insurance coverage expands and treatment affordability improves, more patients are initiating and continuing therapy, thereby driving market growth.

• Growing Geriatric Population

The rising aging population worldwide is contributing to higher incidence and persistence of chronic inflammatory conditions, including psoriasis. Older adults often require consistent disease management, supporting sustained demand for therapeutic products.

• Pipeline Development and Competitive Landscape

Robust research and development activities focused on novel mechanisms of action are strengthening the treatment landscape. The entry of new players and increasing strategic collaborations among pharmaceutical companies are intensifying competition and accelerating innovation within the market.

• Digital Health and Tele Dermatology Expansion

The integration of telemedicine and digital health platforms has improved patient engagement, monitoring, and adherence. Easier access to dermatology consultations is enabling timely treatment initiation, particularly in regions with limited specialist availability.

DelveInsight’s “Mild-to-moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Mild-to-moderate Plaque Psoriasis, historical and forecasted epidemiology as well as the Mild-to-moderate Plaque Psoriasis market trends in the United States, EU4 (Germany, France, Italy, Spain), and  the United Kingdom, and Japan.

The Mild-to-moderate Plaque Psoriasis Treatment Market Report provides current treatment practices, emerging drugs, Mild-to-moderate Plaque Psoriasis market share of the individual therapies, and current and forecasted Mild-to-moderate Plaque Psoriasis market size from 2020 to 2034, segmented by seven major markets. The report also covers current Mild-to-moderate Plaque Psoriasis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Mild-to-moderate Plaque Psoriasis Understanding

The DelveInsight’s Mild-to-moderate Plaque Psoriasis market report gives a thorough understanding of Mild-to-moderate Plaque Psoriasis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Psoriasis is an immune-mediated chronic, skin disease that speeds up the growth cycle of skin cells (skin cells to multiply up to 10 times faster than normal). Psoriasis causes patches of thick red skin and silvery scales, and are extremely itchy in nature. Patches are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The most common type of psoriasis (~80% of all psoriasis cases) is called plaque psoriasis.

Mild-to-moderate Plaque Psoriasis Diagnosis

To diagnose psoriasis, skin, scalp, and nails for signs of the condition is examined. A biopsy is a test in which a pathologist examines skin cells under a microscope to determine whether psoriasis is the cause of symptoms. Dermatologists usually perform what's known as a punch biopsy. Plaque psoriasis is diagnosed through a skin exam, medical history, and sometimes a biopsy or blood tests to rule out other conditions.

Mild-to-moderate Plaque Psoriasis Treatment

According to treatment guidelines from the American Academy of Dermatology (AAD), therapeutic intervention for localized mild-to-moderate plaque psoriasis should begin with patient education and the use of topical corticosteroids with or without coal tar or calcipotriene. Thereafter, anthralin or tazarotene, alone or in combination with steroids, can be used following first-line treatment failure or subsequent loss of response to first-line therapy. Alternatively, if control is difficult to achieve or disease is widespread, phototherapy, with and without drugs such as psoralen or retinoids, may be required. Psoriasis can not be cured, but treatments like topical creams (e.g., corticosteroids) and light therapy can help reduce flare-ups. Treatment aims to control symptoms and prevent severe outbreaks

Mild-to-moderate Plaque Psoriasis Epidemiology

The Mild-to-moderate Plaque Psoriasis epidemiology section provides insights into historical and current Mild-to-moderate Plaque Psoriasis patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Mild-to-moderate Plaque Psoriasis report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings from Mild to Moderate Plaque Psoriasis Epidemiological Analysis

• As per Centers for Disease Control and Prevention (2020), Psoriasis is the most common inflammatory disease in the United States, affecting approximately as many as 7.4 million Americans adults.
• According to Wilson et al. (2009), About 80 to 90% of people living with psoriasis experience plaque psoriasis.
• As per a study by Frow et al. (2020), Psoriasis has a relapsing and remitting nature and affects both sexes equally with an estimated 0.8–2.6% prevalence in the UK. Studies suggest psoriasis is more common in white people and usually develops during adulthood, although epidemiological data on psoriasis in non-white patients is relatively limited. Genetic factors are important, with around 30% of people with psoriasis having an affected first-degree relative and high concordance in monozygotic twins.
• As per a study Psoriasis affects both genders equally. The disorder first appears in individuals between ages 15-22 and then a second peak occurs in individuals aged between 55-70 years.Overall, the disorder appears a few years earlier in females compared to males. Psoriasis is muchmore common in Caucasians but low rates have been reported in Africans and the Japanese.
• In 2024, the United States accounted for around 6,800,000 prevalent cases of plaque psoriasis.These cases are expected to increase in the forecast period (2025-2034).
• According to National Psoriasis Foundation, approximately 125 million people worldwide havepsoriasis, including around 14 million people in Europe and more than 8 millionpeople in theUnited States. About 80-90% of those patients have plaque psoriasis.
• According to Badri et al. (2021), on the basis of severity of psoriasis, 47.1%patients reported mildplaque psoriasis, 39.1% patients reported moderate plaque psoriasis, and 13.8%patients reportedsevere plaque psoriasis.

Country-wise Mild-to-moderate Plaque Psoriasis Epidemiology

The epidemiology segment also provides the Mild-to-moderate Plaque Psoriasis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Mild-to-moderate Plaque Psoriasis Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Plaque Psoriasis in the US
• Total Prevalent Cases of Mild to Moderate Plaque Psoriasis in the US
• Gender-specific Cases of Mild to Moderate Plaque Psoriasis in the US
• Age-specific Cases of Mild to Moderate Plaque Psoriasis in the US
• Total Treated Cases of Mild to Moderate Plaque Psoriasis in the US

Mild-to-moderate Plaque Psoriasis Drugs Analysis

The drug chapter segment of the Mild-to-moderate Plaque Psoriasis Therapeutics Market Report encloses the detailed analysis of Mild-to-moderate Plaque Psoriasis marketed drugs and late-stage (Phase III and Phase II) Mild-to-moderate Plaque Psoriasis Pipeline Drugs. It also helps understand the Mild-to-moderate Plaque Psoriasis Clinical Trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Mild-to-moderate Plaque Psoriasis Marketed Drugs

• Otezla: Amgen

Otezla is the only pill approved to treat mild, moderate, and severe plaque psoriasis. Otezla works to reduce PDE4 activity. PDE4 is an enzyme that is believed to contribute to the inflammation associated with plaque psoriasis, though the exact way in which Otezla helps improve symptoms isn't completely understood.

Note: Detailed Current therapies assessment will be provided in the full report...

Emerging Mild-to-moderate Plaque Psoriasis Drugs

• SGX302: Soligenix 

SGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light.

• AKP02/AKVANO: Lipidor AB

AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO technology. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate plaque psoriasis.

Mild To Moderate Plaque Psoriasis Market Outlook

The Mild To Moderate Plaque Psoriasis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Mild To Moderate Plaque Psoriasis market trends by analyzing the impact of current Mild To Moderate Plaque Psoriasis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Mild To Moderate Plaque Psoriasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Mild To Moderate Plaque Psoriasis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Mild To Moderate Plaque Psoriasis Treatment Market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Mild To Moderate Plaque Psoriasis market in 7MM.

The United States Mild To Moderate Plaque Psoriasis Market Outlook

This section provides the total Mild To Moderate Plaque Psoriasis market size and market size by therapies in the United States.

EU-5 Countries: Mild To Moderate Plaque Psoriasis Market Outlook

The total Mild To Moderate Plaque Psoriasis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Mild To Moderate Plaque Psoriasis Market Outlook

The total Mild To Moderate Plaque Psoriasis market size and market size by therapies in Japan is also mentioned.

Mild To Moderate Plaque Psoriasis Drugs Uptake

This section focuses on the rate of uptake of the potential Mild To Moderate Plaque Psoriasis drugs recently launched in the Mild To Moderate Plaque Psoriasis market or expected to get launched in the market during the study period 2020-2034. The analysis covers Mild To Moderate Plaque Psoriasis market uptake by drugs; patient uptake by therapies; and sales of each drug. Mild To Moderate Plaque Psoriasis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Mild To Moderate Plaque Psoriasis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Mild To Moderate Plaque Psoriasis Clinical Trials Activities

The Mild To Moderate Plaque Psoriasis Therapeutics Market Report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Mild To Moderate Plaque Psoriasis Companies involved in developing targeted therapeutics.

Mild To Moderate Plaque Psoriasis Pipeline Development Activities

The Mild To Moderate Plaque Psoriasis Therapeutics Market Report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Mild To Moderate Plaque Psoriasis emerging therapies.

Mild To Moderate Plaque Psoriasis Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL-Views on Mild To Moderate Plaque Psoriasis

To keep up with current Mild To Moderate Plaque Psoriasis market trends, we take KOLs and SMEs ' opinion working in the Mild To Moderate Plaque Psoriasis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Mild To Moderate Plaque Psoriasis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Mild To Moderate Plaque Psoriasis Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Mild To Moderate Plaque Psoriasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Major Mild To Moderate Plaque Psoriasis Companies

AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, and others.

Scope of the Mild To Moderate Plaque Psoriasis Market Report

• The Mild To Moderate Plaque Psoriasis Therapeutics Market Report covers the descriptive overview, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Mild To Moderate Plaque Psoriasis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Mild To Moderate Plaque Psoriasis is provided, along with the assessment of new therapies, which will have an impact on the current Mild To Moderate Plaque Psoriasis Treatment Market Landscape
• A detailed review of the Mild To Moderate Plaque Psoriasis Treatment Market, historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Mild To Moderate Plaque Psoriasis Therapeutics Market Report provides an edge while developing business strategies, by understanding trends shaping and driving the global Mild To Moderate Plaque Psoriasis market

Mild To Moderate Plaque Psoriasis Market Report Highlights

• In the coming years, the Mild To Moderate Plaque Psoriasis Therapeutics Market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug Mild To Moderate Plaque Psoriasis manufacturers to penetrate more into the market
• The Mild To Moderate Plaque Psoriasis Companies and academics are working to assess challenges and seek opportunities that could influence Mild To Moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major Mild To Moderate Plaque Psoriasis Companies are involved in developing therapies for Mild To Moderate Plaque Psoriasis. The launch of emerging therapies will significantly impact the Mild To Moderate Plaque Psoriasis Drugs Market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Mild To Moderate Plaque Psoriasis
• Our in-depth analysis of the Mild To Moderate Plaque Psoriasis Pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Mild To Moderate Plaque Psoriasis Market Report Insights

• Mild To Moderate Plaque Psoriasis Patient Population
• Therapeutic Approaches
• Mild To Moderate Plaque Psoriasis Pipeline Analysis
• Mild To Moderate Plaque Psoriasis Market Size and Trends
• Mild To Moderate Plaque Psoriasis Drugs Market Opportunities
• Impact of Upcoming Mild To Moderate Plaque Psoriasis Therapies

Mild To Moderate Plaque Psoriasis Market Report Key Strengths

• 11-Year Mild To Moderate Plaque Psoriasis Market Forecast
• 7MM Coverage
• Mild To Moderate Plaque Psoriasis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Mild To Moderate Plaque Psoriasis Drugs Market
• Mild To Moderate Plaque Psoriasis Drugs Uptake

Mild To Moderate Plaque Psoriasis Market Report Assessment

• Current Mild To Moderate Plaque Psoriasis Treatment Practices
• Mild To Moderate Plaque Psoriasis Unmet Needs
• Mild To Moderate Plaque Psoriasis Pipeline Drugs Profiles
• Mild To Moderate Plaque Psoriasis Drugs Market Attractiveness
• Mild To Moderate Plaque Psoriasis Market Drivers and Barriers

Key Questions Answered in the Mild To Moderate Plaque Psoriasis Market Report

Mild To Moderate Plaque Psoriasis Treatment Market Insights:

• What was the Mild To Moderate Plaque Psoriasis drugs market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Mild To Moderate Plaque Psoriasis Market Size as well as market size by therapies across the 7MM during the forecast period (2025-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Mild To Moderate Plaque Psoriasis market size during the forecast period (2025-2034)?
• At what CAGR, the Mild To Moderate Plaque Psoriasis market is expected to grow by 7MM during the forecast period (2025-2034)?
• What would be the Mild To Moderate Plaque Psoriasis market outlook across the 7MM during the forecast period (2025-2034)?
• What would be the Mild To Moderate Plaque Psoriasis market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Mild To Moderate Plaque Psoriasis Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Mild To Moderate Plaque Psoriasis?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Mild To Moderate Plaque Psoriasis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Mild To Moderate Plaque Psoriasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Mild To Moderate Plaque Psoriasis?
• Out of all 7MM countries, which country would have the highest Mild To Moderate Plaque Psoriasis prevalent population during the forecast period (2025-2034)?
• At what CAGR the Mild To Moderate Plaque Psoriasis Patient Population is expected to grow in 7MM during the forecast period (2025-2034)?

Current Mild To Moderate Plaque PsoriasisTreatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Mild To Moderate Plaque Psoriasis treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Mild To Moderate Plaque Psoriasis in the USA, Europe, and Japan?
• What are the Mild To Moderate Plaque Psoriasis marketed drugs and their respective Mild To Moderate Plaque Psoriasis MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Mild To Moderate Plaque Psoriasis?
• How many therapies are in-development by each company for Mild To Moderate Plaque Psoriasis treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Mild To Moderate Plaque Psoriasis treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Mild To Moderate Plaque Psoriasis therapies?
• What are the recent novel therapies, targets, Mild To Moderate Plaque Psoriasis Mechanisms of Action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mild To Moderate Plaque Psoriasis and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Mild To Moderate Plaque Psoriasis?
• What are the global historical and forecasted Mild To Moderate Plaque Psoriasis Market?

Reasons to Buy the Mild To Moderate Plaque Psoriasis Market Report

• The Mild To Moderate Plaque Psoriasis therapeutics market report will help in developing business strategies by understanding trends shaping and driving the Mild To Moderate Plaque Psoriasis drugs market
• To understand the future market competition in the Mild To Moderate Plaque Psoriasis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Mild To Moderate Plaque Psoriasis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the Mild To Moderate Plaque Psoriasis drugs market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Mild To Moderate Plaque Psoriasis drugs market
• To understand the future market competition in the Mild To Moderate Plaque Psoriasis drugs market.

Stay updated with Recent Articles @ New DelveInsight Blogs